We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test 24 Hours After Start of Chemotherapy Predicts Survival

By LabMedica International staff writers
Posted on 11 Jan 2023
Print article
Image: A new method can quickly predict if certain cancer patients will survive or not after chemotherapy (Photo courtesy of Pexels)
Image: A new method can quickly predict if certain cancer patients will survive or not after chemotherapy (Photo courtesy of Pexels)

Acute myeloid leukemia is an aggressive blood cancer with poor survival. Despite high rates of initial chemotherapy response, patients often relapse due to the selection and development of chemotherapy-resistant leukemic cells. The response to therapy is currently measured after weeks to months of treatment, thereby losing important time. Now, researchers have found a new method that within hours can predict if certain cancer patients will survive or not after chemotherapy.

Researchers at the University of Bergen (Bergen, Norway) have discovered that an immediate response to chemotherapy can be measured by investigating the functional properties of the leukemic cells. In their study, the researchers employed mass cytometry to investigate intracellular signaling networks in peripheral blood samples from 32 newly-diagnosed acute myeloid leukemia patients during the first 24 hours of standardized induction chemotherapy. By correlating initial intracellular signaling response to five-year overall survival, the researchers demonstrated that early response evaluation by mass cytometry at 24 hours can identify patients with suboptimal treatment response to standard induction therapy.

"When treating patients with leukemia, it is challenging to quickly follow if the patient is responding to therapy or not," said Benedicte Sjo Tislevoll, researcher at the University of Bergen and leader of the new study. "Our results show that the protein ERK1/2 increases within the first 24 hours of chemotherapy in patients who have a poor response to therapy. We believe that this protein is responsible for the cancer cells' resistance to chemotherapy and can be used to distinguish responders from non-responders."

"We think that this is an important key in our understanding of cancer, and our aim is to use this information to change treatment early for patients who are not responding to therapy," Tislevoll concluded.

Related Links:
University of Bergen 

Flocked Swab
HydraFlock and PurFlock Ultra
New
Gold Supplier
HDL Subfractions Kit
Lipoprint HDL Subfractions Kit
New
C-Reactive Protein Test
STANDARD F hs-CRP FIA
New
Spectrophotometer
UVILINE 9300

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.